Document is current
Any future updates will be listed below
-
Authors
Althammer, Sonja
Tan, Tze Heng
Spitzmüller, Andreas
Rognoni, Lorenz
Wiestler, Tobias
Herz, Thomas
Widmaier, Moritz
Rebelatto, Marlon C.
Kaplon, Helene
Damotte, Diane
Alifano, Marco
Hammond, Scott A.
Dieu-Nosjean, Marie-Caroline
Ranade, Koustubh
Schmidt, Guenter
Higgs, Brandon W.
Steele, Keith E.
-
Funding
Funding for this research was provided by:
AstraZeneca (N/A)
Institut National de la Santé et de la Recherche Médicale (N/A)
Université Pierre et Marie Curie (N/A)
Université Paris Descartes (N/A)
MedImmune (N/A)
Ligue Contre le Cancer
- License Information
-
More Information
Article History
Received: 3 December 2018
Accepted: 2 April 2019
First Online: 6 May 2019
Ethics approval and consent to participate
: Clinical study NCT01693562, from which data in this report were obtained, was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol, amendments, and participant informed consent document were approved by the appropriate institutional review boards.
: No individual data were used in this study.
: SAH, MCR, KR, BWH, and KES are employees of AstraZeneca and own stock and/or stock options in AstraZeneca. THT, AS, LR, TW, TH, MW, and GS are employees of Definiens AG. SA at the time of this study was an employee of Definiens AG.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
